Last updated 6 days ago
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
60 patients around the world
Available in United States, Brazil
Eli Lilly and Company
8Research sites
60Patients around the world
This study is for people with
Crohn's disease
Requirements for the patient
To 80 Years
All Gender
Medical requirements
- Participants must meet all the inclusion criteria in the IIBD master protocol, except the UC-specific criteria. In addition, they must meet the criteria below.Participants taking glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), GLP-1/glucose-dependent insulinotropic polypeptide (GIP) RAs, GLP-1/glucagon (Gcg) RAs, GLP-1/GIP/Gcg RAs, or similar medications for approved indications will be permitted to enroll provided they are on a stable dose at the time of screening.
- Participants are excluded from the study if any of the exclusion criteria in the IIBD master protocol, except the UC-specific criteria apply, or if any of the following criteria apply.Must not have a hepatic disease.Must not have a history of any other bone disease that affects bone metabolism.Must not have had any of the following within the past 180 days before screening.Acute myocardial infarction.Cerebrovascular incident.Hospitalization for unstable angina.Hospitalization due to congestive heart failure.Coronary revascularization.Must not have received or will need any other prohibited medications as specified in the protocol.
Sites
Loema - Instituto de Pesquisa Clinica e Consultores
Instituto de Pesquisas em Saúde - Fundação Universidade de Caxias do Sul (IPS/FUCS)
Centro de Diabetes Curitiba - Curitiba, Parana
CPQuali Pesquisa Clínica
CPClin – Centro de Pesquisas Clinicas LTDA
BR Trials - Pesquisa Clínica - Sao Paulo
Clínica Hepatogastro JK
Cedoes - Pesquisa e Diagnóstico
SponsorEli Lilly and Company
Study typeInterventional
Conditions
Crohn's disease
Requirements
To 80 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07483099
